SNSSのチャート
SNSSの企業情報
| symbol | SNSS |
|---|---|
| 会社名 | Sunesis Pharmaceuticals Inc （サネシス・ファ―マス―ティカルズ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 サネシス・ファーマシューティカルズ(Sunesis Pharmaceuticals Inc.)はバイオ医薬品会社である。同社は血液腫瘍・固形腫瘍の治療を含むがん治療薬の開発及び商品化に集中する。同社は主に急性骨髄性白血病(AML)の治療用の「vosaroxin」の開発に集中する。「voreloxin」は抗癌キノロン誘導体(AQD)である。AQDは、細胞複製のための重要な酵素である哺乳類のトポイソメラーゼIIを標的とすることで抗腫瘍活性を媒介することが示される。同社のVALOR試験はAMLの化学療法であるシタラビン「cytarabine」との組み合わせで「vosaroxin」の効果を評価するために設計される。同試験は適応設計を有し、再発または難治性のAMLでシタラビン「cytarabine」との組み合わせでvosaroxinの同社の第II相臨床試験からのデータに基づく。 サネシス・ファ―マス―ティカルズは米国のバイオ医薬品会社。固形がんと血液がんの治療薬の開発と商品化を行う。急性骨髄性白血病の阻害剤ボサロキシンの研究に焦点を置く。ボサロキシンはキノロン系抗菌剤で、第3相試験を完了し、欧州医薬品庁に販売承認を申請中。また、骨髄異形形成症候群への適応を治験中。 |
| 本社所在地 | 395 Oyster Point Boulevard Suite 400 South San Francisco CA 94080 USA |
| 代表者氏名 | Dayton C. Misfeldt デイトンC.ミスフェルト |
| 代表者役職名 | Interim Chief Executive Officer Director |
| 電話番号 | +1 650-266-3500 |
| 設立年月日 | 35827 |
| 市場名 | NASDAQ Small Cap |
| ipoyear | 2005年 |
| 従業員数 | 39人 |
| url | www.sunesis.com |
| nasdaq_url | https://www.nasdaq.com/symbol/snss |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -30.03600 |
| 終値（lastsale） | 2.19 |
| 時価総額（marketcap） | 79139973.06 |
| 時価総額 | 時価総額（百万ドル） 69.02162 |
| 売上高 | 売上高（百万ドル） 0.23700 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 76.86262 |
| 当期純利益 | 当期純利益（百万ドル） -30.89500 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Sunesis Pharmaceuticals Inc. revenues decreased 65% to $237K. Net loss decreased 24% to $14.1M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Lower net loss reflects Research and development decrease of 29% to $7.4M (expense) Stock-based Compensation in SGA decrease of 64% to $441K (expense). |
SNSSのテクニカル分析
SNSSのニュース
Viracta Therapeutics Announces Closing of Merger with Sunesis Pharmaceuticals and $65M Private Placement 2021/02/24 21:05:00 PR Newswire
SAN DIEGO, Feb. 24, 2021 /PRNewswire/ -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced the closing of its merger with Sunesis Pharmaceuticals, Inc. (previously trading on Nasdaq under "SNSS"). The combined,…
Why Sunesis, Poseida, Salarius And PRA Health Are Rallying 2021/02/24 19:07:31 Benzinga
A slew of healthcare stocks is moving on Wednesday in reaction to company-specific catalysts. Sunesis Rises On Hopes of Completion of Merger Deal: Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS ), a biopharma focused on developing targeted therapies for hematologic and solid cancers, filed its annual report on Form 10-K with the SEC. The company had announced in November an agreement to merge with privately-held precision oncology company Viracta Therapeutics. In an 8-K filing Tuesday, the company said each of the five proposals related to the merger was approved by the requisite vote at the special shareholder meeting held Feb. 22, paving way for the closing of the transaction. Sunesis shares were climbing 26.46% to … Full story available on Benzinga.com
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Sunesis Pharmaceuticals, Inc. - SNSS 2020/12/05 02:13:00 PR Newswire
NEW YORK, Dec. 4, 2020 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating Sunesis Pharmaceuticals, Inc. ("SNSS" or the "Company") (SNSS)…
SUNESIS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Sunesis Pharmaceuticals, Inc. - SNSS 2020/12/03 22:17:00 Business Wire
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Sunesis Pharmaceuticals, Inc. (NasdaqGS: SNSS) with Viracta Therapeutics, Inc. pursuant to which Sunesis shareholders will end up owning just 14% of the combined company, subject to adjustment. KSF is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger u
Sunesis Pharmaceuticals (NASDAQ:SNSS) Trading Up 11.9% 2020/10/23 17:24:50 US Banking News
Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) shares shot up 11.9% during mid-day trading on Friday . The stock traded as high as $1.55 and last traded at $1.46. 1,999,292 shares were traded during trading, an increase of 177% from the average session volume of 721,360 shares. The stock had previously closed at $1.30. A number of analysts […]
Viracta Therapeutics Announces Closing of Merger with Sunesis Pharmaceuticals and $65M Private Placement 2021/02/24 21:05:00 PR Newswire
SAN DIEGO, Feb. 24, 2021 /PRNewswire/ -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced the closing of its merger with Sunesis Pharmaceuticals, Inc. (previously trading on Nasdaq under "SNSS"). The combined,…
Why Sunesis, Poseida, Salarius And PRA Health Are Rallying 2021/02/24 19:07:31 Benzinga
A slew of healthcare stocks is moving on Wednesday in reaction to company-specific catalysts. Sunesis Rises On Hopes of Completion of Merger Deal: Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS ), a biopharma focused on developing targeted therapies for hematologic and solid cancers, filed its annual report on Form 10-K with the SEC. The company had announced in November an agreement to merge with privately-held precision oncology company Viracta Therapeutics. In an 8-K filing Tuesday, the company said each of the five proposals related to the merger was approved by the requisite vote at the special shareholder meeting held Feb. 22, paving way for the closing of the transaction. Sunesis shares were climbing 26.46% to … Full story available on Benzinga.com
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Sunesis Pharmaceuticals, Inc. - SNSS 2020/12/05 02:13:00 PR Newswire
NEW YORK, Dec. 4, 2020 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating Sunesis Pharmaceuticals, Inc. ("SNSS" or the "Company") (SNSS)…
SUNESIS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Sunesis Pharmaceuticals, Inc. - SNSS 2020/12/03 22:17:00 Business Wire
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Sunesis Pharmaceuticals, Inc. (NasdaqGS: SNSS) with Viracta Therapeutics, Inc. pursuant to which Sunesis shareholders will end up owning just 14% of the combined company, subject to adjustment. KSF is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger u
Sunesis Pharmaceuticals (NASDAQ:SNSS) Trading Up 11.9% 2020/10/23 17:24:50 US Banking News
Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) shares shot up 11.9% during mid-day trading on Friday . The stock traded as high as $1.55 and last traded at $1.46. 1,999,292 shares were traded during trading, an increase of 177% from the average session volume of 721,360 shares. The stock had previously closed at $1.30. A number of analysts […]
Viracta Therapeutics Announces Closing of Merger with Sunesis Pharmaceuticals and $65M Private Placement 2021/02/24 21:05:00 PR Newswire
SAN DIEGO, Feb. 24, 2021 /PRNewswire/ -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced the closing of its merger with Sunesis Pharmaceuticals, Inc. (previously trading on Nasdaq under "SNSS"). The combined,…
Why Sunesis, Poseida, Salarius And PRA Health Are Rallying 2021/02/24 19:07:31 Benzinga
A slew of healthcare stocks is moving on Wednesday in reaction to company-specific catalysts. Sunesis Rises On Hopes of Completion of Merger Deal: Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS ), a biopharma focused on developing targeted therapies for hematologic and solid cancers, filed its annual report on Form 10-K with the SEC. The company had announced in November an agreement to merge with privately-held precision oncology company Viracta Therapeutics. In an 8-K filing Tuesday, the company said each of the five proposals related to the merger was approved by the requisite vote at the special shareholder meeting held Feb. 22, paving way for the closing of the transaction. Sunesis shares were climbing 26.46% to … Full story available on Benzinga.com
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Sunesis Pharmaceuticals, Inc. - SNSS 2020/12/05 02:13:00 PR Newswire
NEW YORK, Dec. 4, 2020 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating Sunesis Pharmaceuticals, Inc. ("SNSS" or the "Company") (SNSS)…
SUNESIS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Sunesis Pharmaceuticals, Inc. - SNSS 2020/12/03 22:17:00 Business Wire
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Sunesis Pharmaceuticals, Inc. (NasdaqGS: SNSS) with Viracta Therapeutics, Inc. pursuant to which Sunesis shareholders will end up owning just 14% of the combined company, subject to adjustment. KSF is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger u
Sunesis Pharmaceuticals (NASDAQ:SNSS) Trading Up 11.9% 2020/10/23 17:24:50 US Banking News
Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) shares shot up 11.9% during mid-day trading on Friday . The stock traded as high as $1.55 and last traded at $1.46. 1,999,292 shares were traded during trading, an increase of 177% from the average session volume of 721,360 shares. The stock had previously closed at $1.30. A number of analysts […]